Omeros Corporation has grown revenue 4.4% a year over three years and 40% a year over five, with earnings per share compounding at 38%. Revenue growth, 3-year annual rate: +4.4% (Biotechnology median +17%). Revenue growth, 5-year rate: +40%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +38%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

OMEROmeros Corporation

Healthcare

$10.72+217% 1Y

$10.72

$4.1052 weeks$21.04

Is it growing?

Watch

Earnings down −181% year on year. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 to watch, 2 without data

Earnings trend−181% in a yearSEC EDGAR · Jun 30, 2026

Trailing-twelve-month earnings per share against a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is OMER growing?

Omeros Corporation has grown revenue 4.4% a year over three years and 40% a year over five, with earnings per share compounding at 38%.

+4.4%

Revenue growth, 3-year annual rate · Biotechnology median +17% · growing slowly · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +40%
Revenue growth, 5-year rate · +4.4% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +38%
Earnings per share, 3-year rate · revenue +4.4% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Annual income statements as filed with the SEC.

Biotechnology

Ranks #95 of 196 by RyuScore

Compare peers

DMRA+1.5%

Damora Therapeutics, Inc.

INBX-0.89%

Inhibrx Biosciences, Inc.

NVAX-2.0%

Novavax, Inc.

JBIO+2.6%

Jade Biosciences, Inc.

MPLT-2.8%

MapLight Therapeutics, Inc.

IMTX-0.81%

Immatics N.V.